Oxford Biomedica is a leading, fully integrated, cell and gene therapy group

We have built a sector leading lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of cell and gene therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases.

Oxford Biomedica has entered into a number of partnerships, including with Novartis, Juno Therapeutics/Bristol Myers Squibb, SIO Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations.

Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.

Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people.


Strategy: leveraging our viral vector expertise


LentiVector® platform
Oxford Biomedica’s LentiVector® system is at the heart of the business.

We are driving the industrialisation of lentiviral vectors. We aim to bring down the cost per dose through IP innovation, opening up therapeutic markets currently inaccessible to cell and gene therapy due to the amount (and therefore costs) of the vector required. In addition, the reduction in cost will help drive adoption by payors into indications where there are far larger numbers of patients, by bringing down the overall cost per patient treated.

Our IP, patents and know-how, along with our 20 plus years of expertise in applying our lentiviral vector technology is enabling our customers to bring next generation treatments for serious diseases to market.

See more here.

Our Contract Development and Manufacturing Organisation (CDMO) business provides scale-up solutions and commercial supply of viral vectors to pharmaceutical and biotech companies in the fast-growing cell and gene therapy field.

Oxford Biomedica’s expert professionals use our world-leading facilities to develop and manufacture commercially scalable products for partners.

Our industry leading knowledge in multiple therapeutic areas (gene modified cell therapies, ocular, liver, respiratory diseases and CNS disorder) means we can help solve partners scale-up and supply needs in all of the leading areas in which cell and gene therapy products are being developed.

See more here.

Gene Therapeutics
Oxford Biomedica develops innovative new IP-protected LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

See more here.


Prime Minister Rt Hon Boris Johnson MP formally opening Oxford Biomedica’s new 84,000 sq ft Oxbox manufacturing facility in January 2021.